Cellectis (CLLS) Priced

Developing cancer immunotherapies based on gene-edited CAR T cells.

Health Care - Biotechnology

IPO Performance
Latest Trade $20.04 0.00 (0.0%)
First Day Return -5.3%
Return from IPO -51.7%
 
Cellectis IPO News more
  • .
IPO Data
IPO File Date 02/20/2015
Offer Price $41.50
Price Range $41.50 - $41.50
Offer Shares (mm) 5.5
Deal Size ($mm) 228
 
IPO Data
IPO Date 03/24/2015
Offer Price $41.50
Price Range $41.50 - $41.50
Offer Shares (mm) 5.5
Deal Size ($mm) $228
 
Underwriters
more
Business Overview
Developing cancer immunotherapies based on gene-edited CAR T cells.
Developing cancer immunotherapies based on gene-edited CAR T cells.
more
Company Data
Headquarters Paris, , France
Founded 2000
Employees 93
Website www.cellectis.com
 

Performance vs. IPO Index (IPOUSA)